VEGFC-156S treatment enhanced lymphangiogenesis without affecting hypercholesterolemia but did not improve lymphatic drainage, reduce plasma cholesterol, and atherosclerosis lesion size [86]. The gene discussed is VEGFC; the disease is atherosclerosis.